Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Tolaney

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
ESMO Open|September 13, 2023
Artificial intelligence as an adjunct tool for breast oncologists - are we there yet?I Schlam, M C Saad Menezes, C Corti, et al.
ESMO Open|April 13, 2024
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancerG Curigliano, R Dent, H Earle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2022
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclibP Tarantino, Q Jin, E A Mittendorf, et al.
ESMO Open|September 17, 2024
Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNAA Grinshpun, A Zick, T Perri, et al.
ESMO Open|October 8, 2025
Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world studyS M Tolaney, L Spring, Y G Abdou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Prevalence and mutational determinants of high tumor mutation burden in breast cancerR Barroso-Sousa, E Jain, O Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2013
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancerS M Tolaney, J Najita, J Sperinde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2025
Redefining clinical trial strategic design to support drug approval in medical oncologyG Antonarelli, J M Pérez-García, M Gion, et al.
ESMO Open|September 6, 2024
Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United StatesS M Tolaney, K Punie, L A Carey, et al.
ESMO Open|March 20, 2026
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and AsiaH S Rugo, S M Tolaney, J Cortés, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
ESMO Open|September 13, 2023
Artificial intelligence as an adjunct tool for breast oncologists - are we there yet?I Schlam, M C Saad Menezes, C Corti, et al.
ESMO Open|April 13, 2024
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancerG Curigliano, R Dent, H Earle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2022
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclibP Tarantino, Q Jin, E A Mittendorf, et al.
ESMO Open|September 17, 2024
Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNAA Grinshpun, A Zick, T Perri, et al.
ESMO Open|October 8, 2025
Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world studyS M Tolaney, L Spring, Y G Abdou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Prevalence and mutational determinants of high tumor mutation burden in breast cancerR Barroso-Sousa, E Jain, O Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2013
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancerS M Tolaney, J Najita, J Sperinde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2025
Redefining clinical trial strategic design to support drug approval in medical oncologyG Antonarelli, J M Pérez-García, M Gion, et al.
ESMO Open|September 6, 2024
Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United StatesS M Tolaney, K Punie, L A Carey, et al.
ESMO Open|March 20, 2026
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and AsiaH S Rugo, S M Tolaney, J Cortés, et al.
Pageof 6